Seizure News and Research

Latest Seizure News and Research

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

$Most refractory status epilepticus patients have poor functional outcome$

Most refractory status epilepticus patients have poor functional outcome

Three-quarters of refractory status epilepticus patients have a poor functional outcome, which is linked to drug-induced coma and severe encephalographic suppression, say US scientists.

30 Oct 2012

NEJM report on best options for safe, effective patient treatment against fungal meningitis

As the number of fungal meningitis cases continues to rise, physicians across the country are faced with how best to provide the early treatment that can save lives.

24 Oct 2012

Eisai receives FDA approval for Fycompa to treat partial onset seizures

The U.S. Food and Drug Administration today approved Fycompa (perampanel) tablets to treat partial onset seizures in patients with epilepsy ages 12 years and older.

23 Oct 2012

UCI, Brown work advances quest for novel treatments for inherited disorder

UC Irvine and Brown University researchers have created a new fruit fly model of inherited epilepsy that's providing insights into the mechanisms underlying temperature-dependent seizures while establishing a platform from which to develop therapies for these disorders.

20 Oct 2012

Brown University, UCI researchers create Drosophila fruit fly model of epilepsy

In a newly reported set of experiments that show the value of a particularly precise but difficult genetic engineering technique, researchers at Brown University and the University of California-Irvine have created a Drosophila fruit fly model of epilepsy to discern the mechanism by which temperature-dependent seizures happen.

12 Oct 2012

Three WSU studies could result in new treatments for epilepsy, behavioral disorders

Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.

12 Oct 2012

Translational Genomics Research Institute creates new center for rare childhood disorders

The Translational Genomics Research Institute (TGen) today announced the creation of a new center that could have life changing effects on the lives of potentially thousands of children and their families.

6 Oct 2012

Authorities shut down 18K online pharmacy sites in crackdown of fake drug sales

"Police and regulators around the world have closed 18,000 online pharmacy sites in the past few days, in the largest ever clampdown on criminal gangs selling unauthorized medicines online," the Financial Times reports.

6 Oct 2012

Court approves Abbott settlement for wrongly marketing Depakote

The pharmaceutical company will pay $1.5 billion for marketing the drug for non-approved uses.

4 Oct 2012

First Edition: October 3, 2012

Kaiser Health News staff writer Jordan Rau reports: "Medicare's new readmission penalties for hospitals just got a bit tougher. The Centers for Medicare & Medicaid Services has discovered errors in its initial calculations in August. As a result, 1,422 hospitals with comparatively high readmission rates will lose slightly more money than they were expecting, according to a Kaiser Health News analysis of the revised penalties. Fifty-five hospitals will lose less than were previously told."

3 Oct 2012

More access to video-EEG may reduce treatment gap for epilepsy and PNES

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Longer looks: A 'renegade' Bill Frist?; The pharmacist's expanding role

Meet former Sen. Bill Frist, a renegade "Obamacare"-loving Republican who is in the mood for some real bipartisanship. Yes, the same Frist who as Senate majority leader led an army into the culture wars over Terri Schiavo and whose efforts in 2004 to unseat his then-rival, Minority Leader Tom Daschle, led to a nasty - and personal - Washington battle royal. Now, Frist is pushing for a national conversation on end-of-life care and dismissing "caricatured" talk of death panels.

21 Sep 2012

Study: 46% of living kidney transplant donor recipients are minorities

The largest U.S. multicenter study of living kidney transplant donor chains showed that 46 percent of recipients are minorities, a finding that allays previous fears that these groups would be disadvantaged by expansion of the donor pool through this type of exchange process.

20 Sep 2012

Trigeminal Nerve Stimulation: an interview with Dr Leon Ekchian, President and CEO of NeuroSigma

Trigeminal Nerve Stimulation (TNS) is a novel medical treatment in which mild electrical signals stimulate branches of the trigeminal nerve in order to change the activity of targeted brain regions. The trigeminal nerve is the largest cranial nerve, and provides sensation to the face and head. Because it is a large sensory nerve, the trigeminal offers a high-bandwidth pathway for electrical signals to enter the brain. The brain areas targeted by TNS are known to play key roles in seizures, mood, and attention.

14 Sep 2012

Posterior medial cortex more specifically engaged in recall or imagination

You already know it's hard to balance your checkbook while simultaneously reflecting on your past. Now, investigators at the Stanford University School of Medicine - having done the equivalent of wire-tapping a hard-to-reach region of the brain - can tell us how this impasse arises.

4 Sep 2012

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

1 Sep 2012

Wellness Center USA closes PSI acquisition

Wellness Center USA, Inc., a Schaumburg IL based healthcare and nutraceutical company, reported the closing of its Psoria-Shield Inc. (PSI) acquisition. PSI is a Tampa, FL based developer and manufacturer of UltraViolet (UV) phototherapy devices for the treatment of skin diseases.

29 Aug 2012

New non-invasive brain scan can benefit patients with epileptic seizures

A team of University of Minnesota biomedical engineers and researchers from Mayo Clinic published a groundbreaking study today that outlines how a new type of non-invasive brain scan taken immediately after a seizure gives additional insight into possible causes and treatments for epilepsy patients.

27 Aug 2012